论文部分内容阅读
据估计,今后5年中全球生物医药市场将以年均两位数的速度增长,2006年,生物医药市场总产值将从1999年的200亿美元猛增至700亿美元,其中外协定制生产潜在市场将增至20亿美元。以Bioehemie、Lonza和DSM为代表的传统定制生产企业纷纷扩建生物反应装置,而Avecia、Cambrex、Dow等精细化学品公司也不甘示弱,竞相加入生物医药外协定制行列。
It is estimated that in the next five years, the global biopharmaceutical market will grow at an average double-digit annual rate. In 2006, the total output value of the biopharmaceutical industry will soar to over 70 billion U.S. dollars from 20 billion U.S. dollars in 1999, The potential market will increase to 2 billion U.S. dollars. Traditional custom manufacturing companies represented by Bioehemie, Lonza and DSM have expanded their bioreactors. Fine chemical companies such as Avecia, Cambrex and Dow have also been outdone and are competing to join the biomedical outsourcing agreement.